BrainsWay (BWAY) vs Neuropace (NPCE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BrainsWay (BWAY) has outperformed Neuropace (NPCE) over the past year, gaining 13.9% versus a loss of 44.6%. Over five years, BWAY leads with a +130.7% price change compared with -32.8% for NPCE. BrainsWay is the larger company by market cap ($341.3 million vs $273.9 million), about 1.2 times the size.
BrainsWay converts more of its revenue into profit, with a net margin of 7.1% versus -21.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BWAY | NPCE |
|---|---|---|
| Share price | $8.48 | $7.95 |
| Market cap | $341.35M | $273.89M |
| 1-day change | -2.86% | -2.33% |
| YTD return | -10.83% | -48.51% |
| 1-year return | +13.90% | -44.60% |
| 5-year return | +130.75% | -32.80% |
| P/E ratio (TTM) | 35.33 | — |
| Forward P/E | 16.96 | — |
| EPS (TTM) | $0.24 | $-0.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.02M | $99.99M |
| Revenue growth (YoY) | +29.04% | +25.13% |
| Net income (latest FY) | $2.92M | $-21.46M |
| Gross margin | 74.56% | 77.23% |
| Operating margin | 3.39% | -16.34% |
| Net margin | 7.12% | -21.47% |
| 52-week high | $17.40 | $19.60 |
| 52-week low | $7.30 | $5.46 |
| Distance from 52-week high | -51.26% | -59.44% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +127.24% | +53.71% |
| Average volume | 110.35K | 270.76K |
| Shares outstanding | 40.25M | 34.45M |
| Employees | 129 | 216 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BWAY has outperformed NPCE by 58.5 percentage points over the past year.
- BrainsWay is more profitable, keeping 7.1 cents of every revenue dollar as net income versus -21.5 cents for Neuropace.
About BrainsWay
BWAY stock →BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 129 employees
About Neuropace
NPCE stock →NeuroPace, Inc. operates as a medical device company in the United States.
Health Care · Medical/Dental Instruments · 216 employees
BWAY vs NPCE FAQ
Which is bigger, BrainsWay or Neuropace?
BrainsWay (BWAY) is larger, with a market capitalization of $341.35M compared with $273.89M for Neuropace (NPCE).
Which stock has performed better over the past year, BWAY or NPCE?
BWAY returned +13.90% over the past 12 months, compared with -44.60% for NPCE (price return, excluding dividends). Past performance does not predict future results.
Are BrainsWay and Neuropace in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.